Clinical trials: Glial Tumor
Glioma
Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma
The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).
- Trial name
- GLIOMANOID (NCT03971812)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma
The goal of this clinical trial is to estimate the safety, tolerance and initial efficacy of target IL-13Rα2 or B7-H3 UCAR-T cell injection in the treatment of patients with advanced glioma, as well as the pharmacokinetic…
- Trial name
- NCT05752877
- Testing
- Targeted IL-13 Rα2 UCAR-T cell injection, Targeted B7-H3 UCAR-T cell injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Glioma, Epilepsy
Glioma Intraoperative MicroElectroCorticoGraphy
The goal of this clinical trial is to validate the safety and to assess the quality of the signals provided by newly developed micro ElectroCorticoGraphy electrodes, provided by the company Panaxium, based on conductive polymers…
- Trial name
- MicroECoGG (NCT06408428)
- Testing
- PANAXIUM MicroECoG
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Brain Tumors
A Case-Referent Study of Brain Tumors in Adults
The etiology of brain tumors is poorly understood. Due, in part, to public concern about a postulated relationship between the use of cellular telephones or other increasingly prevalent environmental exposures and the incidence…
- Trial name
- NCT00339300
- Where
- United States
- Volunteers
- 1,581 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma, Glioblastoma Multiforme
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma
- Trial name
- NCT00114309
- Testing
- 131-I-TM-601, 131I-TM601
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- TransMolecular
Anesthesia, Outcome, High-grade Glioma
The Impact of Anesthesia on High- Grade Glioma Patients
Although bench data and retrospective studies have provided a promising picture of the possible influence of anesthetic technique on the risk of tumor progression and patients mortality, current evidence from RCTs is inadequate…
- Trial name
- NCT02756312
- Testing
- IV Anesthesia, IH anesthesia
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Beijing Tiantan Hospital
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
RE-irradiation of Diffuse MIdline Glioma paTients
The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG).
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, Diffuse Glioma, Pontine Tumors
- Trial name
- REMIT (NCT06093165)
- Testing
- Re-irradiation
- Volunteers
- 59 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Brain Tumor, Astrocytoma
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Background: Zotiraciclib (TG02) is an investigational drug that penetrates the blood-brain barrier and might treat brain tumors. Temozolomide (TMZ) is a drug used to treat brain tumors.
- Conditions
- Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma
- Trial name
- NCT02942264
- Testing
- Zotiraciclib (TG02), Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Glioma
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.
- Trial name
- NCT00555399
- Testing
- Vorinostat, Isotretinoin, Surgical Resection
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma, Glioblastoma Multiforme
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024557
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Glioma, Malignant
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients…
- Trial name
- GMCI (NCT03576612)
- Testing
- AdV-tk, Valacyclovir, Radiation
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Candel Therapeutics, Inc.
Glioblastoma Multiforme (GBM)
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
A randomized, double-blind, placebo-controlled study. Weekly ADI-PEG 20 (36 mg/m2) or placebo will be combined with Stupp Protocol (Stupp 2005) radiotherapy and TMZ
- Trial name
- GBM (NCT04587830)
- Testing
- ADI-PEG 20, Temozolomide
- Where
- 10 sites in South Korea, Taiwan
- Volunteers
- 100 people
- Sponsor
- Polaris Group
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Malignant Brain Glioma
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors.
- Trial name
- NCT04908709
- Testing
- Magnetic Resonance Spectroscopic Imaging, Proton Therapy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Glioma, High Grade
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
This clinical trial is designed to evaluate the safety and efficacy of a universal mRNA vaccine targeting a panel of glioma-associated mutations in patients with recurrent or progressive high-grade glioma.
- Trial name
- NCT07306299
- Testing
- Glioma-related multi-target mRNA vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma (GBM)
Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.
- Trial name
- MELODY (NCT07375992)
- Testing
- Music intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Glioma, H3 K27M
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
- Trial name
- NCT04617002
- Testing
- ONC201 (dordaviprone)
- Where
- 23 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Diffuse Intrinsic Pontine Glioma (DIPG)
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
The goal of this pilot study is to determine if intra-arterial (IA) chemotherapy is safe in the treatment of progressive diffuse intrinsic pontine gliomas (DIPG).
- Trial name
- NCT01688401
- Testing
- Melphalan hydrochloride
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Diffuse Glioma
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild…
- Trial name
- NCT04910022
- Testing
- NMS-03305293, Temozolomide
- Where
- 18 sites in United States, Italy and 3 more
- Volunteers
- 150 people
- Sponsor
- Nerviano Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.